Search Results for: Il MMG e le cure palliative. Le cure del medico di famiglia ai malati in fine vita

Nasce Osservatorio su economia salute, monitorerà stili di vita

Esperti,’farmaci e chirurgia utili ma non c’è terapia specifica’

Persiani, ‘possiamo scegliere di modificarli correttamente, a partire dalla dieta’. Attenzione a 4 campanelli d’allarme

Oncologi, ‘per migliore qualità di vita vanno superati i tabu’

In Italia solo il 4% della spesa. Villani, ‘paghi le cure chi li rifiuta’

Al S.Giovanni di Dio Cagliari, riduce ansia e dolore fino al 40%

Colpito da grave infezione. Ricostruite tibia e caviglia

Al Santa Croce di Fano impiantato dispositivo con successo

Objective
Live biotherapeutic products (LBPs) are biological products composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains of Akkermansia muciniphila and Christensenella minuta, as well as treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need for guidelines over the increasing interest in developing LBPs. A panel of microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations for LBP development.

Design
Experts in microbiome research, microbiology, gastroenterology, internal medicine and biotherapeutics industry were invited to form a panel. During the 2023 Inauguration Conference of the Asia-Pacific Microbiota Consortium, an organised, iterative roundtable discussion was conducted to build expert consensus on critical issues surrounding the development of LBP.

Results
The consensus statements were organised into three main aspects: (a) rationales of LBP development, (b) preclinical studies and (c) preparation for clinical studies. The panel strongly recommended to prioritise human-derived and food-sourced strains for development, with indications based on clinical need and efficacy shown in studies. Preclinical evaluation should involve thorough screening, genotyping and phenotyping, as well as comprehensive in vitro and animal studies to assess functional mechanisms and microbiological safety. Rigorous cell banking practices and genetic monitoring are essential to ensure product consistency and safety throughout the manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed and closely monitored, with robust safety and risk management protocols in place.

Conclusions
The development of LBP should be approached with a strong emphasis on microbiological evaluation, clinical relevance, scientific mechanisms and safety at every stage. These measures are essential to ensure the safety, effectiveness and long-term success of the product.

Rete Città Sane, luoghi di vita quotidiana decisivi per salute

‘Non c’è dono più grande di quello che salva una vita’

Presidente consiglio comunale e medico sulla Nave della Salute

No al fumo e controllo della pressione sono le principali

A rischio settore dei farmaci generici-equivalenti e biosimilari

Cergas-Bocconi,4 milioni non autosufficienti e la domanda cresce

A Torino. Anelli, ‘medici siano messi in condizione di lavorare’. Balzanelli, ‘urge riforma per potenziare sistema d’emergenza’